#Finland #Helsinki #Bioretec Ltd #Kustaa Poutiainen #orthopedic solutions

Bioretec Ltd Appoints New Board Members Amid Strategic Innovations

On May 8, 2026, Bioretec Ltd, a leading innovator in orthopedic medical devices based in Finland, held its constitutive meeting following the Annual General Meeting. The meeting resulted in significant changes to the company’s leadership and board structure, as well as the reinforcement of its commitment to advancing orthopedic care.

New Board Appointments

The Board of Directors has elected Kustaa Poutiainen to serve as the Chairperson, with David Gill stepping in as the Deputy Chairperson. These appointments are expected to bring a wealth of experience and strategic vision to the company's operations. The board also saw the formation of essential committees to oversee critical aspects of governance.

• - Audit Committee: Chaired by Päivi Malinen, with members Michael Piccirillo and David Gill.
• - Remuneration Committee: Led by Justin Barad alongside Antti Vasara and Michael Piccirillo.

A thorough assessment of the members' independence was conducted, adhering to the Finnish Corporate Governance Code. The board concluded that all members, with the exception of Kustaa Poutiainen, are independent of Bioretec and its main shareholders. Poutiainen is deemed independent of the company itself but maintains ties with significant shareholder Stephen Industries Inc Oy, where he serves as Chairperson.

Overview of Bioretec’s Innovations

Bioretec is recognized for its pioneering role in developing biodegradable implant technologies that enhance orthopedic procedures. The company specializes in creating active implants that promote bone growth and facilitate fracture healing, a critical advancement for orthopedic surgery outcomes. Among its innovations is the RemeOs™ product line, which utilizes a high-performance magnesium alloy and hybrid composite.

The RemeOs implants provide a novel solution by being fully absorbable, thus eliminating the need for subsequent removal surgeries after the healing process, which can sometimes hinder recovery. The introduction of these implants significantly improves surgical outcomes, setting a new standard in orthopedic science. The first authorization for sale of the RemeOs product occurred in the U.S. in March 2023, while European approval was secured with a CE mark in January 2025.

In addition to RemeOs, the Activa product line showcases Bioretec’s commitment to bioabsorbable orthopedic implants crafted from proprietary materials, which are both CE marked and FDA cleared for diverse indications in both adult and pediatric care.

Looking to the Future

Bioretec Ltd is poised to reshape the landscape of orthopedic treatment through its innovative approach that emphasizes healing via absorption. As they continue to push technological boundaries and improve patient outcomes, Bioretec remains dedicated to providing effective and patient-friendly solutions in medical care.

For further insights into Bioretec’s transformative work in orthopedic technology, visit their official website at www.bioretec.com.

In conclusion, the recent changes in Bioretec’s Board coupled with their innovative product offerings indicate a future-oriented approach to orthopedic care, positioning the company as a frontrunner in the medical device sector.